BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16437336)

  • 21. The treatment of anemia in peritoneal dialysis patients.
    Lacson E; Diaz-Buxo JA
    Clin Nephrol; 2001 Dec; 56(6):415-27. PubMed ID: 11770793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Peritoneal dialysis in patients with chronic kidney-graft failure].
    Puttinger H
    Wien Klin Wochenschr; 2005; 117 Suppl 6():35-9. PubMed ID: 16437331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
    Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adequate peritoneal dialysis--new guidelines?].
    Lilaj T
    Wien Klin Wochenschr; 2005; 117 Suppl 6():83-8. PubMed ID: 16437338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Iron therapy: is it different with peritoneal dialysis compared to haemodialysis?].
    Durand PY
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S341-6. PubMed ID: 17373281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anemia syndrome in patients with chronic renal insufficiency on peritoneal dialysis treated with recombinant erythropoietin].
    Romanova LA; Lugovskaia SA; Khareb F; Shumov EV; Shmarov DA
    Urologiia; 2002; (5):26-30. PubMed ID: 12402772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Peritoneal dialysis and cardiopulmonary comorbidity].
    Wiesholzer M
    Wien Klin Wochenschr; 2005; 117 Suppl 6():46-53. PubMed ID: 16437333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ; Abid K; Ambreen F; Qureshi AL
    Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
    Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of renal anemia.
    Peco-Antic A
    Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.